RT Journal Article
SR Electronic
T1 Prediction of Therapeutic Effects from One Course of TPF Chemotherapy for Advanced Hypopharyngeal Laryngeal Cancer
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 2891
OP 2896
DO 10.21873/invivo.12117
VO 34
IS 5
A1 RYO MARUYAMA
A1 ISAKU OKAMOTO
A1 HIROKI SATO
A1 YASUAKI KATSUBE
A1 TAKAHITO KONDO
A1 KIYOAKI TSUKAHARA
YR 2020
UL http://iv.iiarjournals.org/content/34/5/2891.abstract
AB Background: In head and neck cancer, docetaxel, cisplatin and 5-fluorouracil (TPF) is often given in two or three cycles. The purpose of this study was to perform single-cycle TPF for chemoselection in patients with advanced hypopharyngeal laryngeal cancer. Patients and Methods: The study included 56 patients with stage III/IV advanced hypopharyngeal/laryngeal squamous cell carcinoma. The primary endpoint was progression-free survival (PFS), and secondary endpoints were overall survival (OS), TPF response rate, laryngeal sparing, and grade 3 or more adverse events. Results: The median PFS was 34.8 months. The median OS was not evaluable. The response rate was 71%. The median laryngeal preservation period was not estimable. Grade 3 or 4 adverse events were reported in 46 patients. Conclusion: PFS rate in this study may have been improved by selecting surgical treatment for patients for whom chemoradiotherapy seemed less effective. One cycle of TPF in induction chemotherapy appeared effective for chemoselection.